Business Description
Enlivex Therapeutics Ltd
ISIN : IL0011319527
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 31.07 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22 | |||||
3-Year EPS without NRI Growth Rate | -20.2 | |||||
3-Year FCF Growth Rate | -11.9 | |||||
3-Year Book Growth Rate | -12.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 21.67 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.05 | |||||
9-Day RSI | 57.7 | |||||
14-Day RSI | 59.04 | |||||
6-1 Month Momentum % | -65.74 | |||||
12-1 Month Momentum % | -32.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.06 | |||||
Quick Ratio | 10.06 | |||||
Cash Ratio | 9.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.4 | |||||
Shareholder Yield % | -6.26 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -66.11 | |||||
ROA % | -55.81 | |||||
ROIC % | -174.14 | |||||
3-Year ROIIC % | -684.15 | |||||
ROC (Joel Greenblatt) % | -259.41 | |||||
ROCE % | -52.43 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.08 | |||||
Price-to-Tangible-Book | 1.08 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-EBITDA | -0.37 | |||||
EV-to-FCF | -0.38 | |||||
Price-to-Net-Current-Asset-Value | 1.22 | |||||
Price-to-Net-Cash | 1.37 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -54.03 |